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Abstract: Objective:  
To examine evidence on the economic impact of electronic prescribing (EP) 
systems in the hospital setting. 
Method:  
We conducted a systematic search of MEDLINE, EMBASE, PsycINFO, 
International Pharmaceutical Abstracts, the NHS Economic Evaluation 
Database, the European Network of Health Economic Evaluation Database and 
Web of Science from inception to October 2013. Full and partial economic 
evaluations of EP or computerised provider order entry were included. We 
excluded studies assessing prescribing packages for specific drugs, and 
monetary outcomes that were not related to medicines. A checklist was 
used to evaluate risk of bias and evidence quality.  
Results:    
The search yielded 1,160 articles of which three met the inclusion 
criteria.  Two were full economic evaluations and one a partial economic 
evaluation. A meta-analysis wasn't appropriate as studies were 
heterogeneous in design, economic evaluation method, interventions and 
outcome measures.  Two studies investigated the financial impact of 
reducing preventable adverse drug events. The third measured savings 
related to various aspects of the system including those related to 
medication. Two studies reported positive financial effects. However the 
overall quality of the economic evidence was low and key details often 
not reported.  
Discussion 
There seems to be some evidence of financial benefits of EP in the 
hospital setting. However, it is not clear if evidence is transferable to 
other settings. Research is scarce and limited in quality, and reported 
methods are not always transparent. Further robust, high quality research 
is required to establish if hospital EP is cost effective and thus inform 
policy makers' decisions.   
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systematic search of seven databases from inception to October 2013 and included full and partial 
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Objective:  
To examine evidence on the economic impact of electronic prescribing (EP) systems in the hospital 
setting. 
Method:  
We conducted a systematic search of MEDLINE, EMBASE, PsycINFO, International Pharmaceutical 
Abstracts, the NHS Economic Evaluation Database, the European Network of Health Economic 
Evaluation Database and Web of Science from inception to October 2013. Full and partial economic 
evaluations of EP or computerised provider order entry were included. We excluded studies 
assessing prescribing packages for specific drugs, and monetary outcomes that were not related to 
medicines. A checklist was used to evaluate risk of bias and evidence quality.  
Results:    
The search yielded 1,160 articles of which three met the inclusion criteria.  Two were full economic 
evaluations and one a partial economic evaluation. A meta-analysis wasn’t appropriate as studies 
were heterogeneous in design, economic evaluation method, interventions and outcome measures.  
Two studies investigated the financial impact of reducing preventable adverse drug events. The third 
measured savings related to various aspects of the system including those related to medication. 
Two studies reported positive financial effects. However the overall quality of the economic 
evidence was low and key details often not reported.  
Discussion 
There seems to be some evidence of financial benefits of EP in the hospital setting. However, it is not 
clear if evidence is transferable to other settings. Research is scarce and limited in quality, and 
reported methods are not always transparent. Further robust, high quality research is required to 
establish if hospital EP is cost effective and thus inform policy makers’ decisions.   
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1. Introduction 
Government policies are increasingly promoting the use of technology in healthcare. In May 2013, 
the English Health Secretary announced a £250 million “safer hospitals, safer wards” technology 
fund for English NHS trusts, aiming for technology delivery in 2015 [1]. This fund was doubled in 
September 2013 with the goal of facilitating greater access to information for healthcare 
professionals. These steps mirror US government legislation to spread meaningful use of healthcare 
information technology through the Medicare and Medicaid incentive program [2]. 
The use of electronic prescribing (EP) systems in English hospital is expanding [3].  EP systems can 
reduce medication errors [4-8] and increase efficiency [9].  However, similar to most technologies, 
they are also associated with substantial acquisition costs and on-going support costs; enormous 
organisational change is also likely to be required [10]. Estimates of up to $8 million for 
implementation of computerised provider order entry (CPOE) in a 500-bed US hospital have been 
reported [11], where CPOE may be used for ordering other investigations and treatments as well as 
medication. The challenge that most healthcare organisations face under the current financial 
climate is reducing costs and increasing productivity while improving quality. Therefore, many 
healthcare institutions are seeking evidence about the economic impact of technology adoption to 
better inform decisions about the optimal choice and implementation strategy. 
There are limited data about the cost effectiveness of adopting technology in healthcare settings [9]. 
This may be due to the complexity of estimating and identifying factors contributing to direct and 
intangible costs and benefits of technology use. Moreover, variations in study designs and systems 
used in the literature make it difficult to extrapolate data to other settings.  Previous reviews in this 
area have explored the economic effects of a wide range of technological interventions in various 
healthcare settings [12-14]. In contrast, our review specifically focuses on EP and the medication-
related aspects of CPOE in the hospital setting.  
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2. Objective: 
To examine the available evidence about the economic impact of EP systems in the hospital setting. 
3. Methods: 
3.1 Search strategy: 
We followed the PRISMA guidelines for reporting systematic reviews and meta-analyses [15]. A 
review protocol guide was developed. A structured electronic search strategy was developed and 
carried out in the following databases: The Cochrane Library, MEDLINE, EMBASE, PsycINFO, 
International Pharmaceutical Abstracts, the NHS Economic Evaluation Database, the European 
Network of Health Economic Evaluation Database and the Web of Science for conference 
proceedings up to Oct 2013. We searched for facets relating to (1) EP/CPOE and (2) economic 
evaluation. Details of the MEDLINE search strategy are available as supplementary material.  
References in relevant previous reviews were screened [12-14]. Five key journals were screened 
manually for papers published between 2006 and 2013:  International Journal of Technology 
Assessment in Health Care, International Journal of Healthcare Technology and Management, 
Journal of the American Medical Informatics Association, Journal of Evaluation in Clinical Practice 
and Journal of Health Economics.  
3.2 Inclusion and exclusion criteria: 
We included any full or partial economic evaluation studies of EP and/or CPOE in hospitals published 
in English. Full economic evaluation was defined as the comparative analysis of alternative courses 
of action in terms of both costs and consequences [16]. Full economic evaluations thus included cost 
effectiveness analysis (CEA), cost utility analysis (CUA) and cost benefit analysis (CBA). Studies that 
reported costs (resource use) and/or monetary consequences but did not make explicit comparisons 
between alternative interventions in terms of both costs and consequences were considered partial 
economic evaluations [17].  
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To be included, studies had to assess electronic systems that allow healthcare professionals to order 
or prescribe medication orders electronically.  We were interested in systems used for prescribing a 
wide range of drugs for either general hospital populations or specific populations such as 
paediatrics.  Therefore, we excluded studies assessing prescribing packages aimed at specific 
group(s) of drugs. Where a system was used to order more than just medicines, monetary outcome 
measures unrelated to medicines were excluded. Inclusion and exclusion criteria are summarised in 
table 1.  
3.3 Study selection and data extraction: 
Article abstracts and titles were initially screened by one researcher (ZA) and assessed against our 
criteria. For all papers which potentially met the inclusion criteria, or if there was any doubt, the full 
text was obtained and evaluated using an assessment sheet.  A 10% random sample of the abstracts 
and titles screened, and of the full text articles screened, were reviewed by a second researcher 
(SG). Data extraction from included papers was conducted independently by two researchers (ZA & 
YJ) using an extraction template. Extracted data included setting, design, intervention, comparator, 
population, outcome measures, and type of economic evaluation.  For both study selection and data 
extraction, disagreement was resolved by consensus and if necessary review by a third researcher 
(BDF). 
3.4 Study appraisal and analysis:   
Assessment of risk of bias and study quality was carried out using the checklist of Drummond et al 
[18]. Studies were classified and organised according to design and type of economic evaluation.  
4. Results 
The electronic search resulted in 1,160 unique articles after removing 205 duplicates (Figure 1). 
Three databases didn’t yield any relevant papers (PSYCHINFO, The Cochrane Library, and the 
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European Network of Health Economic Evaluation database). There was 91% (105 of 116) agreement 
between reviewers for screening of title & abstract, and 100% (n=3) for full text review. 
4.1 Study characteristics: 
Three studies [19-21] (table 2) met our inclusion criteria, of which two were full economic 
evaluations [19, 20] and one a partial economic evaluation [21]. One study was conducted in the US 
[21], one in Canada [20] and one in the UK [19]. One [21] was based in a single tertiary care hospital 
and one in a multi-site healthcare institution [20]. The remaining study had no actual setting and all 
cost estimates were based on a theoretical model of a 400 bed acute UK hospital using a 
hypothetical system [19].  Interventions and comparators also varied. Interventions included were 
described as CPOE [19, 21] of which one was home grown [21], and a commercial medication order 
entry system combined with medication administration records [20]. The clinical decision support 
system capabilities of the interventions assessed were described fully in one study [20] partially in 
another [21] and the remaining study did not provide any description [19]. Given the small number 
of studies which met our inclusion criteria and their heterogeneity, meta-analysis was not possible.  
We therefore undertook a narrative synthesis of the findings. 
4.2 Economic impact assessment:  
Methods used to assess the financial impact of the technology varied. The three studies all reported 
monetary outcomes specifically related to medicines (table 2), of which two investigated the 
financial impact of reducing preventable adverse drug events [19, 20]. The third measured savings 
related to various aspects of a CPOE system and displayed a breakdown of savings associated with 
different aspects including those related to medicines [21].  
Two studies showed favourable economic impact [19, 21]. Karnon et al [19] developed a decision 
tree model to estimate the net benefits of three interventions (CPOE, ward pharmacists, and bar 
coding) aimed at reducing medication errors using information obtained from a systematic review of 
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the literature. Lower and upper estimates for implementation and maintenance costs of a 
hypothetical CPOE system in a 400 bed hospital were used in the model including potential 
efficiency savings (reduced medication costs, range: £75,000-150,000) from the deployment of 
CPOE. Estimated resource requirements for the additional treatment of ADEs, and monetary 
valuations of the health effects of ADEs on patients were also included in the analysis [19]. Karnon 
and colleagues found CPOE to be associated with no probability of producing positive net financial 
benefits when only health service costs were considered. However, a net benefit of CPOE with a 
mean estimate of around £31.5 million over five years was predicted when monetary value of lost 
health (due to preventable adverse drug events) was included in the analysis.  In a separate study, 
Wu et al reported incremental costs for the intervention compared with a conventional approach of 
a total of USD$ 3,322,000 over a 10 year horizon [20]. These authors also estimated an incremental 
cost-effectiveness of $12,700 per adverse drug event prevented after system implementation [20]. 
This was found to be sensitive to the adverse drug event rate, the effectiveness of the new system in 
preventing adverse drug events, the cost of the system, and costs due to possible increases in doctor 
workload. Authors estimated acquisition costs of USD $1.4 million, implementation costs of $1.7 
million and operating costs of $19,652 per year [20]. Estimates of the effect of the system were 
obtained from the literature while cost data were obtained from a health care institution in Toronto, 
Canada in which the study was based.  The remaining paper was a partial economic evaluation which 
reported savings in various outcome measures, with a breakdown of each outcome measure 
separately [21]. Authors of this study estimated upfront costs of development and implementation 
of a CPOE system to be USD$ 11.8 million. Over ten years, the system saved $28.5 million resulting in 
a cumulative net savings of $16.7 million and net operating budget savings of $9.5 million. However, 
the full financial effect of system implementation was not evaluated.  Of the total system savings, 
60% were medication related savings (17.1 million). About 65% (11.1 million) of medication related 
savings were through decreased ADEs, while the remaining 35% (6 million) were cash savings due to 
decreased drug use, frequency, or savings due to IV to oral medicine switch.  
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4.3 Risk of bias and quality assessment and limitations of the studies:  
Overall, studies were found to vary significantly in the quality and transparency of the reporting of 
both methods and results. Although the research questions were clearly stated in all three studies, 
justification for the type of economic analysis performed was not given.  Some details about data 
collection and analysis were lacking. Although details of the selected time horizon for benefits and 
the approach to price discounting (converting prices to present values) were reported, the choices 
were rarely justified. Many of the data used in the evaluations were also based on assumptions 
which were not clearly justified and generalisability issues were not always addressed. For example, 
Karnon et al [19] developed a decision model of a UK hospital but included data from the US that 
might not be appropriate for the UK context. In another study, costs and benefits were assumed to 
be equally affected by inflation although they were assessed at different points in the model [21]. 
Results relating to quality assessment of the included studies are available as supplementary 
material. 
 
5. Discussion 
This is the first review of the financial effects of EP systems in secondary care. Despite widespread 
uptake of EP, it seems that there are few evaluations of the cost effectiveness of this technology 
within this context. In addition, one of the three included studies was not specifically designed to 
capture the full economic impact of EP system implementation as it was carried out retrospectively 
[21].  
Our review findings are consistent with previous reviews in the area of health information 
technology [9, 12-14]. There are issues surrounding the reliability and quality of the methods used in 
published economic evaluations.  The choice of economic evaluation type in relation to the research 
question was not justified by the authors in any of our included studies. Hidden costs and potential 
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savings were not taken fully into account in all the studies. In some cases, costing data were 
obtained from the literature and/or expert estimates which might not be appropriate for the setting 
concerned. The effect of inflation and currency value was not taken into account or assumed to be 
stable over time in one of the studies identified. Moreover, justification for the choices of currency 
rates and discounting was often not given. Generalisability issues were not appropriately addressed 
which makes extrapolating evidence from literature to other settings difficult.  
Our review also showed that level of clinical decision support system was often not described in 
published economic evaluations of EP and CPOE. Such information is important for any meaningful 
assessment of benefits as the level and maturity of clinical decision support system is likely to have 
an influence on costs and benefits achieved. Moreover, systems continue to evolve over time and 
consequently any benefits are likely to be incremental. Therefore the level of evidence is weak and 
not sufficiently robust to establish clear recommendations. 
5.1 Implications for clinical practice  
Adopting new technology such as EP systems in hospital setting needs to be driven by formal 
evaluations. Our review shows that the literature evaluating the economic impact of such systems is 
limited. There seems to be some suggestion of financial benefit when implementing EP in hospital 
settings. However, it is not clear if this evidence is consistent or generalisable. There is little research 
output addressing economic evaluations of technology implementation as these projects tend to 
raise unique local issues [22]. Furthermore, expected financial impact is likely to depend on several 
factors including successful implementation, training, and how the technology is used in practice. 
Moreover, EP economic evaluation studies are challenging due to the diffuse effect of EP on many 
clinical processes across an institution [23]. Our review shows that studies exploring the economic 
impact of EP in this context are scarce. This is further complicated by quality issues and the lack of 
transparency in reported methods as well as assessment of only a limited range of variables related 
to EP use. Further research is required to establish if EP use in secondary care is good value for 
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money. Systems’ software capabilities and costs continue to change, therefore providing details of 
the systems evaluated including software versions and decision support capabilities is essential in 
this field. We argue that planning for concurrent prospective economic evaluations before system 
implementation is vital to capture expected benefits and to inform policy makers. Involvement of a 
health economist at an early stage is therefore advisable. 
5.2 Limitation of this review 
We only included articles published in English.  We were not able to include some economic 
evaluations of CPOE where systems were used for ordering more than just medicines if studies did 
not report the financial impact related to medications separately [6, 24, 25]. There were also two 
recent papers that couldn’t be included as it was not possible to separate the cost outcomes of EP or 
CPOE from those of a wider intervention such as an electronic health record [26, 27].   
 
6. Conclusion: 
In spite of the issues surrounding the quality and robustness EP economic evaluations, the very small 
pool of evidence seems to suggest that there may be potential financial benefits related to EP 
adoption in the hospital setting. Other benefits may provide value to patients through reducing 
errors, improving quality, and increasing efficiency. However, it is difficult to reach any definitive 
conclusion as to whether EP provides value for money due to uncertainty surrounding the costs and 
outcomes, as well limitations in study design. Ensuring better quality and reporting in future 
economic evaluations is necessary to fill the knowledge gap and inform policy makers’ future 
decisions.   
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Objective:  
To examine evidence on the economic impact of electronic prescribing (EP) systems in the hospital 
setting. 
Method:  
We conducted a systematic search of MEDLINE, EMBASE, PsycINFO, International Pharmaceutical 
Abstracts, the NHS Economic Evaluation Database, the European Network of Health Economic 
Evaluation Database and Web of Science from inception to October 2013. Full and partial economic 
evaluations of EP or computerised provider order entry were included. We excluded studies 
assessing prescribing packages for specific drugs, and monetary outcomes that were not related to 
medicines. A checklist was used to evaluate risk of bias and evidence quality.  
Results:    
The search yielded 1,160 articles of which three met the inclusion criteria.  Two were full economic 
evaluations and one a partial economic evaluation. A meta-analysis wasn’t appropriate as studies 
were heterogeneous in design, economic evaluation method, interventions and outcome measures.  
Two studies investigated the financial impact of reducing preventable adverse drug events. The third 
measured savings related to various aspects of the system including those related to medication. 
Two studies reported positive financial effects. However the overall quality of the economic 
evidence was low and key details often not reported.  
Discussion 
There seems to be some evidence of financial benefits of EP in the hospital setting. However, it is not 
clear if evidence is transferable to other settings. Research is scarce and limited in quality, and 
reported methods are not always transparent. Further robust, high quality research is required to 
establish if hospital EP is cost effective and thus inform policy makers’ decisions.   
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1. Introduction 
Government policies are increasingly promoting the use of technology in healthcare. In May 2013, 
the English Health Secretary announced a £250 million “safer hospitals, safer wards” technology 
fund for English NHS trusts, aiming for technology delivery in 2015 [1]. This fund was doubled in 
September 2013 with the goal of facilitating greater access to information for healthcare 
professionals. These steps mirror US government legislation to spread meaningful use of healthcare 
information technology through the Medicare and Medicaid incentive program [2]. 
The use of electronic prescribing (EP) systems in English hospital is expanding [3].  EP systems can 
reduce medication errors [4-8] and increase efficiency [9].  However, similar to most technologies, 
they are also associated with substantial acquisition costs and on-going support costs; enormous 
organisational change is also likely to be required [10]. Estimates of up to $8 million for 
implementation of computerised provider order entry (CPOE) in a 500-bed US hospital have been 
reported [11], where CPOE may be used for ordering other investigations and treatments as well as 
medication. The challenge that most healthcare organisations face under the current financial 
climate is reducing costs and increasing productivity while improving quality. Therefore, many 
healthcare institutions are seeking evidence about the economic impact of technology adoption to 
better inform decisions about the optimal choice and implementation strategy. 
There are limited data about the cost effectiveness of adopting technology in healthcare settings [9]. 
This may be due to the complexity of estimating and identifying factors contributing to direct and 
intangible costs and benefits of technology use. Moreover, variations in study designs and systems 
used in the literature make it difficult to extrapolate data to other settings.  Previous reviews in this 
area have explored the economic effects of a wide range of technological interventions in various 
healthcare settings [12-14]. In contrast, our review specifically focuses on EP and the medication-
related aspects of CPOE in the hospital setting.  
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2. Objective: 
To examine the available evidence about the economic impact of EP systems in the hospital setting. 
3. Methods: 
3.1 Search strategy: 
We followed the PRISMA guidelines for reporting systematic reviews and meta-analyses [15]. A 
review protocol guide was developed. A structured electronic search strategy was developed and 
carried out in the following databases: The Cochrane Library, MEDLINE, EMBASE, PsycINFO, 
International Pharmaceutical Abstracts, the NHS Economic Evaluation Database, the European 
Network of Health Economic Evaluation Database and the Web of Science for conference 
proceedings up to Oct 2013. We searched for facets relating to (1) EP/CPOE and (2) economic 
evaluation. Details of the MEDLINE search strategy are available as supplementary material.  
References in relevant previous reviews were screened [12-14]. Five key journals were screened 
manually for papers published between 2006 and 2013:  International Journal of Technology 
Assessment in Health Care, International Journal of Healthcare Technology and Management, 
Journal of the American Medical Informatics Association, Journal of Evaluation in Clinical Practice 
and Journal of Health Economics.  
3.2 Inclusion and exclusion criteria: 
We included any full or partial economic evaluation studies of EP and/or CPOE in hospitals published 
in English. Full economic evaluation was defined as the comparative analysis of alternative courses 
of action in terms of both costs and consequences [16]. Full economic evaluations thus included cost 
effectiveness analysis (CEA), cost utility analysis (CUA) and cost benefit analysis (CBA). Studies that 
reported costs (resource use) and/or monetary consequences but did not make explicit comparisons 
between alternative interventions in terms of both costs and consequences were considered partial 
economic evaluations [17].  
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To be included, studies had to assess electronic systems that allow healthcare professionals to order 
or prescribe medication orders electronically.  We were interested in systems used for prescribing a 
wide range of drugs for either general hospital populations or specific populations such as 
paediatrics.  Therefore, we excluded studies assessing prescribing packages aimed at specific 
group(s) of drugs. Where a system was used to order more than just medicines, monetary outcome 
measures unrelated to medicines were excluded. Inclusion and exclusion criteria are summarised in 
table 1.  
3.3 Study selection and data extraction: 
Article abstracts and titles were initially screened by one researcher (ZA) and assessed against our 
criteria. For all papers which potentially met the inclusion criteria, or if there was any doubt, the full 
text was obtained and evaluated using an assessment sheet.  A 10% random sample of the abstracts 
and titles screened, and of the full text articles screened, were reviewed by a second researcher 
(SG). Data extraction from included papers was conducted independently by two researchers (ZA & 
YJ) using an extraction template. Extracted data included setting, design, intervention, comparator, 
population, outcome measures, and type of economic evaluation.  For both study selection and data 
extraction, disagreement was resolved by consensus and if necessary review by a third researcher 
(BDF). 
3.4 Study appraisal and analysis:   
Assessment of risk of bias and study quality was carried out using the checklist of Drummond et al 
[18]. Studies were classified and organised according to design and type of economic evaluation.  
4. Results 
The electronic search resulted in 1,160 unique articles after removing 205 duplicates (Figure 1). 
Three databases didn’t yield any relevant papers (PSYCHINFO, The Cochrane Library, and the 
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European Network of Health Economic Evaluation database). There was 91% (105 of 116) agreement 
between reviewers for screening of title & abstract, and 100% (n=3) for full text review. 
4.1 Study characteristics: 
Three studies [19-21] (table 2) met our inclusion criteria, of which two were full economic 
evaluations [19, 20] and one a partial economic evaluation [21]. One study was conducted in the US 
[21], one in Canada [20] and one in the UK [19]. One [21] was based in a single tertiary care hospital 
and one in a multi-site healthcare institution [20]. The remaining study had no actual setting and all 
cost estimates were based on a theoretical model of a 400 bed acute UK hospital using a 
hypothetical system [19].  Interventions and comparators also varied. Interventions included were 
described as CPOE [19, 21] of which one was home grown [21], and a commercial medication order 
entry system combined with medication administration records [20]. The clinical decision support 
system capabilities of the interventions assessed were described fully in one study [20] partially in 
another [21] and the remaining study did not provide any description [19]. Given the small number 
of studies which met our inclusion criteria and their heterogeneity, meta-analysis was not possible.  
We therefore undertook a narrative synthesis of the findings. 
4.2 Economic impact assessment:  
Methods used to assess the financial impact of the technology varied. The three studies all reported 
monetary outcomes specifically related to medicines (table 2), of which two investigated the 
financial impact of reducing preventable adverse drug events [19, 20]. The third measured savings 
related to various aspects of a CPOE system and displayed a breakdown of savings associated with 
different aspects including those related to medicines [21].  
Two studies showed favourable economic impact [19, 21]. Karnon et al [19] developed a decision 
tree model to estimate the net benefits of three interventions (CPOE, ward pharmacists, and bar 
coding) aimed at reducing medication errors using information obtained from a systematic review of 
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the literature. Lower and upper estimates for implementation and maintenance costs of a 
hypothetical CPOE system in a 400 bed hospital were used in the model including potential 
efficiency savings (reduced medication costs, range: £75,000-150,000) from the deployment of 
CPOE. Estimated resource requirements for the additional treatment of ADEs, and monetary 
valuations of the health effects of ADEs on patients were also included in the analysis [19]. Karnon 
and colleagues found CPOE to be associated with no probability of producing positive net financial 
benefits when only health service costs were considered. However, a net benefit of CPOE with a 
mean estimate of around £31.5 million over five years was predicted when monetary value of lost 
health (due to preventable adverse drug events) was included in the analysis.  In a separate study, 
Wu et al reported incremental costs for the intervention compared with a conventional approach of 
a total of USD$ 3,322,000 over a 10 year horizon [20]. These authors also estimated an incremental 
cost-effectiveness of $12,700 per adverse drug event prevented after system implementation [20]. 
This was found to be sensitive to the adverse drug event rate, the effectiveness of the new system in 
preventing adverse drug events, the cost of the system, and costs due to possible increases in doctor 
workload. Authors estimated acquisition costs of USD $1.4 million, implementation costs of $1.7 
million and operating costs of $19,652 per year [20]. Estimates of the effect of the system were 
obtained from the literature while cost data were obtained from a health care institution in Toronto, 
Canada in which the study was based.  The remaining paper was a partial economic evaluation which 
reported savings in various outcome measures, with a breakdown of each outcome measure 
separately [21]. Authors of this study estimated upfront costs of development and implementation 
of a CPOE system to be USD$ 11.8 million. Over ten years, the system saved $28.5 million resulting in 
a cumulative net savings of $16.7 million and net operating budget savings of $9.5 million. However, 
the full financial effect of system implementation was not evaluated.  Of the total system savings, 
60% were medication related savings (17.1 million). About 65% (11.1 million) of medication related 
savings were through decreased ADEs, while the remaining 35% (6 million) were cash savings due to 
decreased drug use, frequency, or savings due to IV to oral medicine switch.  
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4.3 Risk of bias and quality assessment and limitations of the studies:  
Overall, studies were found to vary significantly in the quality and transparency of the reporting of 
both methods and results. Although the research questions were clearly stated in all three studies, 
justification for the type of economic analysis performed was not given.  Some details about data 
collection and analysis were lacking. Although details of the selected time horizon for benefits and 
the approach to price discounting (converting prices to present values) were reported, the choices 
were rarely justified. Many of the data used in the evaluations were also based on assumptions 
which were not clearly justified and generalisability issues were not always addressed. For example, 
Karnon et al [19] developed a decision model of a UK hospital but included data from the US that 
might not be appropriate for the UK context. In another study, costs and benefits were assumed to 
be equally affected by inflation although they were assessed at different points in the model [21]. 
Results relating to quality assessment of the included studies are available as supplementary 
material. 
 
5. Discussion 
This is the first review of the financial effects of EP systems in secondary care. Despite widespread 
uptake of EP, it seems that there are few evaluations of the cost effectiveness of this technology 
within this context. In addition, one of the three included studies was not specifically designed to 
capture the full economic impact of EP system implementation as it was carried out retrospectively 
[21].  
Our review findings are consistent with previous reviews in the area of health information 
technology [9, 12-14]. There are issues surrounding the reliability and quality of the methods used in 
published economic evaluations.  The choice of economic evaluation type in relation to the research 
question was not justified by the authors in any of our included studies. Hidden costs and potential 
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savings were not taken fully into account in all the studies. In some cases, costing data were 
obtained from the literature and/or expert estimates which might not be appropriate for the setting 
concerned. The effect of inflation and currency value was not taken into account or assumed to be 
stable over time in one of the studies identified. Moreover, justification for the choices of currency 
rates and discounting was often not given. Generalisability issues were not appropriately addressed 
which makes extrapolating evidence from literature to other settings difficult.  
Our review also showed that level of clinical decision support system was often not described in 
published economic evaluations of EP and CPOE. Such information is important for any meaningful 
assessment of benefits as the level and maturity of clinical decision support system is likely to have 
an influence on costs and benefits achieved. Moreover, systems continue to evolve over time and 
consequently any benefits are likely to be incremental. Therefore the level of evidence is weak and 
not sufficiently robust to establish clear recommendations. 
5.1 Implications for clinical practice  
Adopting new technology such as EP systems in hospital setting needs to be driven by formal 
evaluations. Our review shows that the literature evaluating the economic impact of such systems is 
limited. There seems to be some suggestion of financial benefit when implementing EP in hospital 
settings. However, it is not clear if this evidence is consistent or generalisable. There is little research 
output addressing economic evaluations of technology implementation as these projects tend to 
raise unique local issues [22]. Furthermore, expected financial impact is likely to depend on several 
factors including successful implementation, training, and how the technology is used in practice. 
Moreover, EP economic evaluation studies are challenging due to the diffuse effect of EP on many 
clinical processes across an institution [23]. Our review shows that studies exploring the economic 
impact of EP in this context are scarce. This is further complicated by quality issues and the lack of 
transparency in reported methods as well as assessment of only a limited range of variables related 
to EP use. Further research is required to establish if EP use in secondary care is good value for 
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money. Systems’ software capabilities and costs continue to change, therefore providing details of 
the systems evaluated including software versions and decision support capabilities is essential in 
this field. We argue that planning for concurrent prospective economic evaluations before system 
implementation is vital to capture expected benefits and to inform policy makers. Involvement of a 
health economist at an early stage is therefore advisable. 
5.2 Limitation of this review 
We only included articles published in English.  We were not able to include some economic 
evaluations of CPOE where systems were used for ordering more than just medicines if studies did 
not report the financial impact related to medications separately [6, 24, 25]. There were also two 
recent papers that couldn’t be included as it was not possible to separate the cost outcomes of EP or 
CPOE from those of a wider intervention such as an electronic health record [26, 27].   
 
6. Conclusion: 
In spite of the issues surrounding the quality and robustness EP economic evaluations, the very small 
pool of evidence seems to suggest that there may be potential financial benefits related to EP 
adoption in the hospital setting. Other benefits may provide value to patients through reducing 
errors, improving quality, and increasing efficiency. However, it is difficult to reach any definitive 
conclusion as to whether EP provides value for money due to uncertainty surrounding the costs and 
outcomes, as well limitations in study design. Ensuring better quality and reporting in future 
economic evaluations is necessary to fill the knowledge gap and inform policy makers’ future 
decisions.   
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What was already known on the topic 
 
 Acquisition costs of health information interventions such as electronic prescribing (EP) 
systems are high.    
 Evidence for the economic benefits of health information technology interventions in 
healthcare is limited. 
 
What this study added to our knowledge 
 
 Evaluation studies exploring the economic impact of EP in the context  of secondary care are 
scarce 
 A small pool of evidence seems to suggest that there are potential financial benefits related 
to EP adoption, particularly if indirect costs and/or societal health gains are considered. 
 Studies varied significantly in quality and transparency of reporting their methods and 
results 
 Ensuring better quality in future economic evaluations is necessary to fill the knowledge gap 
and inform policy makers’ future decisions.   
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Table 1: Inclusion and exclusion criteria  
Criterion  Inclusion Exclusion  
Study design Randomised controlled trials, controlled 
clinical trials, before/after studies or 
interrupted time series studies, cohort 
studies or economic evaluation studies with 
or without modelling techniques. 
------ 
Type of economic 
evaluation  
Full and partial economic evaluations  ------- 
Setting Secondary and tertiary care settings. This 
included general hospitals, speciality 
hospitals, acute and foundation trusts 
Primary care, ambulatory care, 
community hospitals  and long 
term care facilities such as 
nursing or residential homes 
Participants  Any patient group was included 
e.g. general hospital populations or specific 
populations such as paediatrics.   
 
Intervention Electronic prescribing (EP) systems or 
computerised provider order entry (CPOE) 
systems used for prescribing a wide range of 
drugs for in-patients and/or at discharge 
from hospital. 
EP or CPOE systems introduced 
at the same time as other 
interventions e.g. electronic 
health records where the 
impact couldn’t be separated. 
 
Prescribing packages or 
software used only for a 
specific class of drugs. 
Outcome 
measures 
Any economic outcome measure related to 
medicines. 
Non-monetary outcomes. 
 
Monetary outcomes of CPOE 
use where outcomes measures 
related to medicines couldn’t 
be separated from outcomes of 
other aspects of the system. 
Language  English All other languages 
Data extraction Full text could be obtained  Only abstract could be obtained 
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Table 2: Summary of the articles reporting economic outcomes directly related to medication 
Year 
Author 
country 
Type of 
economic 
evaluation  
Study aim Study design & setting Intervention 
& comparator 
(system name 
and version)  
Time 
horizon  
Population Effect measures Currency (year) & 
cost elements 
Main economic findings 
2008 
 
Karnon 
et al 
 
UK [18] 
 Full 
economic 
evaluation 
(Cost utility 
analysis) 
To estimate the 
potential costs 
and benefits of 
three key 
interventions 
that aim to 
reduce the 
impact of 
medication 
errors 
Modelling structure developed 
to describe the incidence and 
impacts of medication errors 
on hospitals’ costs. This model 
included a decision tree to 
describe a series of error points 
and subsequent error detection 
points in pathways through the 
medication process. 
 
No actual setting 
(A theoretical model of a 400-
bed acute hospital) 
CPOE/CDSS 
vs. ward 
pharmacists 
vs. bar coding 
theoretical 
system 
 
5 year 
time 
horizon 
The model was 
populated with 
quantitative 
estimates of the 
incidence and 
impacts of MEs. The 
potential 
effectiveness of 
interventions was 
described by 
estimating its impact 
on error incidence 
and detection rates. 
Quality of life  
utility 
decrements  
associated with 
experiencing a 
pADE  
 
UK. sterling (2006) 
 
Interventions, 
efficiency savings, 
treatment of, and 
the health effects of 
pADEs. 
Health service costs only: CPOE was 
associated with no probability of 
producing positive net benefits. 
Monetary value of lost health 
included: Estimated monetary 
valuations of the health effects of 
pADEs A net benefit with a mean 
estimate of around £31.5 million for 
CPOE over five-years. 
2007 
 
Wu et al 
 
Canada 
[19] 
Full 
economic 
evaluation 
(Cost 
effectivenes
s analysis) 
To determine 
the potential 
incremental 
cost-
effectiveness of 
an e-MOE/MAR 
system 
An incremental cost-
effectiveness analysis was 
performed comparing an 
MOE/MAR to the standard 
system used 
 
University Health Network  is 
an association of three 
University of Toronto teaching 
hospitals (700 beds in total) 
MOE/MAR 
with CDSS vs. 
standard 
paper 
ordering  
 (misys CPR® 
, Misys 
Healthcare 
Systems) 
version not 
specified 
a 10-
year 
time 
horizon 
with 5% 
discount 
rate) 
………. Reduction of 
pADEs and 
associated 
mortality (from 
literature) 
USD (2004)  
 
Implementation 
costs (software, 
project 
management, 
clinical team 
involvement and 
training); operating 
costs (support for 
new interface, 
training)) 
The incremental costs for the MOE 
compared with a conventional 
approach were $3 322 000 over the 10-
year. The incremental cost-
effectiveness of the new system was 
$12 700 (USD) per ADE prevented.  
 
The cost-effectiveness was found to be 
sensitive to the ADE rate, the 
effectiveness of the new system, the 
cost of the system, and costs due to 
possible increase in doctor workload. 
2006 
 
Kaushal 
et al 
 
USA 
[20] 
Partial 
economic 
evaluation 
 
To assess the 
costs and 
financial 
benefits of the 
CPOE system 
over ten years 
Cost and benefit estimates of a 
hospital CPOE system 
 
720 bed, adult tertiary care 
academic hospital. (Brigham 
and 
Women’s Hospital) 
CPOE with 
CDSS  
(home grown 
system) 
version not 
specified 
10 years 
(with 
7% 
discount
ing) 
patients admitted 
between 
1993 and2002 
Reductions in 
ADEs,LOS, 
proportion of 
appropriate 
prescriptions 
laboratory and 
radiology tests 
(some 
measures from 
the literature) 
USD  2002  
 
Capital and 
operational costs, 
drug costs, hospital 
costs 
Between 1993 and 2002, the 
Birmingham Women Hospital spent 
$11.8 million to develop, implement, 
and operate CPOE. Over ten years, the 
system saved BWH $28.5 million (17.1 
million were directly related to 
medications prescribing) for 
cumulative net savings of $16.7 million 
and net operating budget savings of 
$9.5 million given the institutional 80% 
prospective reimbursement rate. 
LOS: length of stay; CPOE: computerized physician order entry; pADEs: preventable adverse drug reactions; e-MOE: electronic medication order entry 
system; MAR: medication administration record; USD: US dollars; CDSS: clinical decision support system. 
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 Evaluations of EP economics in the context of secondary care are limited  
Findings suggests potential financial benefits related to EP use in hospitals 
The evidence is weak and not sufficiently robust to establish clear recommendations 
Further high quality research is required to better inform policy makers and adopters 
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